JP2019535265A - 幹細胞由来シュワン細胞 - Google Patents

幹細胞由来シュワン細胞 Download PDF

Info

Publication number
JP2019535265A
JP2019535265A JP2019524951A JP2019524951A JP2019535265A JP 2019535265 A JP2019535265 A JP 2019535265A JP 2019524951 A JP2019524951 A JP 2019524951A JP 2019524951 A JP2019524951 A JP 2019524951A JP 2019535265 A JP2019535265 A JP 2019535265A
Authority
JP
Japan
Prior art keywords
days
population
cells
cell
differentiated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535265A5 (enExample
Inventor
ローレンツ スチューダー，
ローレンツ スチューダー，
ファラナク ファタヒ，
ファラナク ファタヒ，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2019535265A publication Critical patent/JP2019535265A/ja
Publication of JP2019535265A5 publication Critical patent/JP2019535265A5/ja
Priority to JP2022072292A priority Critical patent/JP2022090133A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2019524951A 2016-11-14 2017-11-14 幹細胞由来シュワン細胞 Pending JP2019535265A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022072292A JP2022090133A (ja) 2016-11-14 2022-04-26 幹細胞由来シュワン細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421816P 2016-11-14 2016-11-14
US62/421,816 2016-11-14
PCT/US2017/061541 WO2018090002A1 (en) 2016-11-14 2017-11-14 Stem cell derived schwann cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022072292A Division JP2022090133A (ja) 2016-11-14 2022-04-26 幹細胞由来シュワン細胞

Publications (2)

Publication Number Publication Date
JP2019535265A true JP2019535265A (ja) 2019-12-12
JP2019535265A5 JP2019535265A5 (enExample) 2021-04-08

Family

ID=62110088

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019524951A Pending JP2019535265A (ja) 2016-11-14 2017-11-14 幹細胞由来シュワン細胞
JP2019524940A Pending JP2019535263A (ja) 2016-11-14 2017-11-14 幹細胞由来シュワン細胞を使用する薬物発見のための方法
JP2022022796A Pending JP2022059056A (ja) 2016-11-14 2022-02-17 幹細胞由来シュワン細胞を使用する薬物発見のための方法
JP2022072292A Pending JP2022090133A (ja) 2016-11-14 2022-04-26 幹細胞由来シュワン細胞

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019524940A Pending JP2019535263A (ja) 2016-11-14 2017-11-14 幹細胞由来シュワン細胞を使用する薬物発見のための方法
JP2022022796A Pending JP2022059056A (ja) 2016-11-14 2022-02-17 幹細胞由来シュワン細胞を使用する薬物発見のための方法
JP2022072292A Pending JP2022090133A (ja) 2016-11-14 2022-04-26 幹細胞由来シュワン細胞

Country Status (9)

Country Link
US (2) US20190331666A1 (enExample)
EP (2) EP3538115A4 (enExample)
JP (4) JP2019535265A (enExample)
KR (1) KR20190077095A (enExample)
CN (2) CN110691601A (enExample)
AU (2) AU2017357072A1 (enExample)
CA (2) CA3043223A1 (enExample)
IL (2) IL266524A (enExample)
WO (2) WO2018090002A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021166984A1 (ja) * 2020-02-20 2021-08-26 株式会社幹細胞＆デバイス研究所 ミエリン化神経細胞を含む神経細胞デバイスの製造方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
CN111655336A (zh) * 2017-11-17 2020-09-11 纽约州立大学研究基金会 使用x射线微束辐射治疗受损周围神经的方法
AU2018379993A1 (en) * 2017-12-04 2020-07-02 Axosim, Inc. Cell systems using spheroids and methods of making and using the same
AU2020210630B2 (en) 2019-01-23 2025-10-23 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
CN113966396A (zh) 2019-05-07 2022-01-21 迈阿密大学 遗传性神经病和相关障碍的治疗和检测
CN110157660A (zh) * 2019-06-10 2019-08-23 西安飞如生物科技有限公司 诱导成纤维细胞分泌抗菌肽的诱导培养基和方法、成纤维细胞及应用
EP3929281A1 (en) 2020-06-24 2021-12-29 Fachhochschule Technikum Wien Cell construct comprising schwann cells or schwann cell-like cells and a biocompatible matrix
EP4298219A1 (en) 2021-02-26 2024-01-03 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
AU2022291933A1 (en) * 2021-06-18 2024-01-18 Memorial Hospital For Cancer And Allied Diseases Methods of generating sacral neural crest lineages and uses thereof
EP4573186A1 (en) * 2022-08-16 2025-06-25 The Regents Of The University Of California Cell compositions and methods of using the same
WO2025170529A1 (en) 2024-02-09 2025-08-14 Hedlund Eva A method for deriving a multipotent neuromesodermal progenitor cell and/or daughter lineages, and related compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016039462A1 (ja) * 2014-09-12 2016-03-17 京都府公立大学法人 シュワン細胞及びその調製方法
JP2016528451A (ja) * 2013-07-30 2016-09-15 ウオーターズ・テクノロジーズ・コーポレイシヨン 高分子の座およびポペット弁を有するチェック弁
WO2016187135A1 (en) * 2015-05-19 2016-11-24 Maya Sieber-Blum Epidermal neural crest stem cells as a source of schwann cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023568A2 (en) * 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
CN101066472B (zh) * 2007-04-18 2010-05-19 中国人民解放军第二军医大学 组织工程化周围神经移植体及其制备方法
JP5751548B2 (ja) * 2009-08-07 2015-07-22 国立大学法人京都大学 イヌｉＰＳ細胞及びその製造方法
WO2011046189A1 (ja) * 2009-10-15 2011-04-21 国立大学法人京都大学 神経変性疾患のモデル細胞、その製造方法及びその用途
CN102191217A (zh) * 2010-03-12 2011-09-21 上海市第一人民医院 一种诱导脐带间充质干细胞分化为类神经细胞的方法
DK2577318T3 (da) * 2010-05-25 2019-10-07 Memorial Sloan Kettering Cancer Center Fremgangsmåde til nociceptor-differentiering af humane embryoniske stamceller og anvendelser deraf
BR112013008957A2 (pt) * 2010-10-15 2019-09-24 Univ Cornell composições e métodos para tratamento de doenças endócrinas, gastrointestinais ou autoimunes
WO2012112933A1 (en) * 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
EP2614829A1 (en) * 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
KR20160033703A (ko) * 2013-07-23 2016-03-28 에프. 호프만-라 로슈 아게 체세포로부터 신경 능선 세포로의 소분자 기반 전환
GB201318126D0 (en) * 2013-10-14 2013-11-27 Univ Cardiff Neuronal Stem Cell Differentiation
CA2931334A1 (en) 2013-11-21 2015-05-28 Memorial Sloan-Kettering Cancer Center Specification of functional cranial placode derivatives from human pluripotent stem cells
KR101903458B1 (ko) * 2017-01-20 2018-10-02 한국생명공학연구원 슈반 세포 전구체 (Schwann cell precursor) 및 이로부터 분화된 슈반 세포 (Schwann cell)의 제조 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528451A (ja) * 2013-07-30 2016-09-15 ウオーターズ・テクノロジーズ・コーポレイシヨン 高分子の座およびポペット弁を有するチェック弁
WO2016039462A1 (ja) * 2014-09-12 2016-03-17 京都府公立大学法人 シュワン細胞及びその調製方法
WO2016187135A1 (en) * 2015-05-19 2016-11-24 Maya Sieber-Blum Epidermal neural crest stem cells as a source of schwann cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MA, MING-SAN, ET AL.: ""Pluripotent Stem Cells for Schwann Cell Engineering."", STEM CELL REVIEWS AND REPORTS, vol. 11, no. 2, JPN6021042607, 2015, pages 205 - 218, XP035485514, ISSN: 0004838374, DOI: 10.1007/s12015-014-9577-1 *
MICA, Y., ET AL.: ""Modeling Neural Crest Induction, Melanocyte Specification, and Disease-Related Pigmentation Defects", CELL REPORTS, vol. 3, no. 4, JPN6021042598, 2013, pages 1140 - 1152, XP055241410, ISSN: 0004838376, DOI: 10.1016/j.celrep.2013.03.025 *
SAKAUE, M., ET AL.: ""Human epidermal neural crest stem cells as a source of Schwann cells."", DEVELOPMENT, vol. 142, JPN6021042603, 2015, pages 3188 - 3197, XP055664270, ISSN: 0004838373, DOI: 10.1242/dev.123034 *
THOMA, E.C., ET AL.: ""Chemical Conversion of Human Fibroblasts into Functional Schwann Cells."", STEM CELL REPORTS, vol. 3, no. 4, JPN6021042606, 2014, pages 539 - 547, XP055675890, ISSN: 0004838375, DOI: 10.1016/j.stemcr.2014.07.014 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021166984A1 (ja) * 2020-02-20 2021-08-26 株式会社幹細胞＆デバイス研究所 ミエリン化神経細胞を含む神経細胞デバイスの製造方法

Also Published As

Publication number Publication date
CN110249047A (zh) 2019-09-17
CN110691601A (zh) 2020-01-14
AU2017357076A1 (en) 2019-05-30
JP2019535263A (ja) 2019-12-12
CA3043226A1 (en) 2018-05-17
EP3538115A4 (en) 2020-04-22
US20190331666A1 (en) 2019-10-31
EP3538110A1 (en) 2019-09-18
WO2018090006A1 (en) 2018-05-17
EP3538110A4 (en) 2020-04-22
IL266524A (en) 2019-07-31
AU2017357072A1 (en) 2019-05-30
EP3538115A1 (en) 2019-09-18
KR20190077095A (ko) 2019-07-02
JP2022059056A (ja) 2022-04-12
CA3043223A1 (en) 2018-05-17
WO2018090002A1 (en) 2018-05-17
IL266554A (en) 2019-07-31
JP2022090133A (ja) 2022-06-16
US20190264173A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
JP2022090133A (ja) 幹細胞由来シュワン細胞
JP7737787B2 (ja) 中脳ドーパミン（ｍＤＡ）ニューロンのｉｎ ｖｉｔｒｏ分化の方法
Zholudeva et al. Transplantation of neural progenitors and V2a interneurons after spinal cord injury
US20230323294A1 (en) Differentiation of cortical neurons from human pluripotent stem cells
CN114650836B (zh) 中脑多巴胺神经元的产生和分离方法
JP2023156413A (ja) 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法
WO2021224496A1 (en) Methods for differentiating stem cells into dopaminergic progenitor cells
US20220323507A1 (en) Method for Producing Cell Aggregate Including Glial Progenitor Cells
US20180231524A1 (en) In vitro methods of identifying modulators of neuromuscular junction activity
WO2025003393A1 (en) Enhancing neuronal differentiation of neural progenitor cells
HK40075940A (en) Methods of generating and isolating midbrain dopamine neurons
Saxena Neural crest-derived sympathoadrenergic-like progenitors of the postnatal murine adrenal gland

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230426